GURU.Markets stock price, segment price, and overall market index valuation
The company's share price CMMB
Chemomab is an Israeli biotech company. Its stock price is a bet on its lead drug candidate for treating rare inflammatory diseases. Its price is volatile and driven by clinical trial news.
Share prices of companies in the market segment - Specialized pharma
Chemomab Therapeutics is an Israeli biopharmaceutical company developing antibodies for the treatment of fibroinflammatory diseases of the liver, skin, and joints. We classified it as a "Specialty Pharmaceutical." The chart below shows how the market values companies fighting fibrosis.
Broad Market Index - GURU.Markets
Chemomab is an Israeli biotech company developing antibody-based drugs for the treatment of fibrotic and inflammatory diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Chemomab shares correlate with sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
CMMB - Daily change in the company's share price CMMB
For Chemomab Therapeutics Ltd., which develops drugs for fibroinflammatory diseases, daily volatility reflects sensitivity to clinical trial data. This metric is key for assessing risks in biotech.
Daily change in the price of a set of shares in a market segment - Specialized pharma
Chemomab Therapeutics Ltd. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with CMMB, which focuses on treating inflammatory diseases, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Chemomab is an Israeli biotech company developing drugs for the treatment of fibrotic diseases. Its shares are driven by news of clinical trials, adding an element of high scientific volatility to the overall market picture.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization CMMB
Chemomab Therapeutics' year-to-date performance is a story of developing a drug to treat rare fibroinflammatory diseases of the liver and skin. Its 12-month market cap is entirely dependent on clinical trial data. The success of its unique antibody could offer new hope for patients with limited treatment options.
Annual dynamics of market capitalization of the market segment - Specialized pharma
As an early-stage biotech company, Chemomab is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its drugs. Its stock price will reflect investors' speculative faith in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Chemomab Therapeutics, focused on rare diseases, is a biotech whose value is locked into a single key drug. Its performance relative to the market is a pure bet on clinical trial success. Positive data could trigger explosive growth, ignoring any market downturns.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization CMMB
Chemomab is an Israeli clinical-stage biopharmaceutical company. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its lead drug for the treatment of fibroinflammatory diseases is a key event for investors.
Monthly dynamics of market capitalization of the market segment - Specialized pharma
Chemomab Therapeutics is a clinical-stage biotech company developing antibodies for the treatment of rare fibroinflammatory diseases of the liver and skin. The chart below illustrates the overall dynamics of the biotech sector, where a focus on rare diseases can lead to the creation of breakthrough drugs.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Chemomab Therapeutics is a clinical-stage biotech developing drugs to treat rare inflammatory diseases. Its shares are buoyed by anticipation of trial results. Positive data can trigger explosive growth, while failures can lead to a collapse, and these events are in no way related to the overall state of the stock market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization CMMB
Chemomab Therapeutics is a biopharmaceutical company developing therapies for the treatment of fibroinflammatory diseases. Its weekly stock price is volatile and depends on the progress of its clinical programs.
Weekly dynamics of market capitalization of the market segment - Specialized pharma
Chemomab Therapeutics is a biotech company whose shares can be highly volatile. The chart helps separate the wheat from the chaff: are the weekly fluctuations caused by unique developments in the company's developments or are they simply a reflection of the general sentiment in the specialty pharmaceutical sector?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Chemomab Therapeutics is a pharmaceutical company whose stock moves to the rhythm of news about clinical trials and partnerships. The chart clearly shows how its weekly performance is detached from the broader market, moving along its own unique trajectory.
Market capitalization of the company, segment and market as a whole
CMMB - Market capitalization of the company CMMB
The Chemomab Therapeutics chart is a curve of hopes for the treatment of rare fibrotic diseases. This biotech company's market cap reflects investor confidence in its lead drug candidate. Its dynamics are a direct response to clinical trial data and regulatory decisions.
CMMB - Share of the company's market capitalization CMMB within the market segment - Specialized pharma
Chemomab Therapeutics is a biopharmaceutical company developing drugs for the treatment of fibroinflammatory diseases. In the specialty pharmaceuticals segment, its market capitalization reflects the potential of its lead drug candidate. The company's market capitalization reflects its bet on clinical success, which could open a multibillion-dollar market.
Market capitalization of the market segment - Specialized pharma
Chemomab Therapeutics fights fibrosis and inflammation. How big is this arena? The chart below shows the overall market capitalization of the specialty pharmaceutical sector. Its growth reflects the massive investment in drug discovery for the underlying diseases of many chronic conditions.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Chemomab Therapeutics chart shows how the market is pricing in the development of a drug for the treatment of rare fibrotic and inflammatory diseases of the liver and skin. Its market cap is based on the unique mechanism of action of its antibody. This diagram illustrates how highly targeted science is finding its application.
Book value capitalization of the company, segment and market as a whole
CMMB - Book value capitalization of the company CMMB
For Chemomab Therapeutics, a biopharmaceutical company, book value is its material basis, consisting of the rights to unique antibodies and financial reserves for clinical trials. The chart below shows how this critical scientific and financial foundation has evolved.
CMMB - Share of the company's book capitalization CMMB within the market segment - Specialized pharma
Chemomab Therapeutics is a biopharmaceutical company whose tangible assets are the research laboratories where its unique antibody for the treatment of fibroinflammatory diseases is being developed. The chart shows the share of this specialized R&D infrastructure within its therapeutic niche that the company controls.
Market segment balance sheet capitalization - Specialized pharma
Chemomab is a biopharmaceutical company. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. Chemomab focuses on drug development, and its capital is intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Chemomab's assets are not factories, but a scientific platform and capital for developing a unique antibody aimed at combating fibrosis and inflammation in liver and skin diseases. Its book value reflects its financial resources for clinical trials.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - CMMB
Chemomab is a biotech company developing antibodies to treat fibrotic and inflammatory diseases. Its market capitalization is a bet on its lead drug. The chart shows how investors react to clinical trial data, which could either confirm or refute its scientific hypothesis.
Market to book capitalization ratio in a market segment - Specialized pharma
Chemomab Therapeutics is a biotech company developing drugs to treat fibroinflammatory diseases. Its value depends on the success of clinical trials. The chart reflects investor expectations for its lead drug compared to its current assets.
Market to book capitalization ratio for the market as a whole
Chemomab Therapeutics is a biotech company developing drugs to treat rare diseases. Its value is derived from its intellectual property and the hopes of successful clinical trials. This chart demonstrates how biotech valuations reflect the potential future market size of a drug, not its current assets.
Debts of the company, segment and market as a whole
CMMB - Company debts CMMB
Chemomab Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat fibroinflammatory diseases. Conducting clinical trials for these chronic conditions can be particularly lengthy and expensive. This chart shows how the company funds its multi-year research and development to bring a new class of drugs to market.
Market segment debts - Specialized pharma
Chemomab Therapeutics is a clinical-stage biotech developing drugs to treat rare fibroinflammatory diseases. Its financial survival depends entirely on its ability to raise capital to conduct lengthy and expensive clinical trials. This chart shows its cash reserves and how quickly they are being burned.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio CMMB
Chemomab Therapeutics is a clinical-stage biopharmaceutical company. This chart shows its financial structure. For a biotech company developing drugs for rare diseases but without revenue, debt is a significant risk. The ability to continue research depends on raising equity rather than debt capital.
Market segment debt to market segment book capitalization - Specialized pharma
Chemomab Therapeutics is a biopharmaceutical company developing antibodies to treat fibroinflammatory diseases. This is a complex and promising field. The chart shows the overall debt burden in the pharmaceutical industry, providing context for assessing how the company finances its lengthy and expensive clinical trials.
Debt to book value of all companies in the market
Chemomab Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat rare fibrotic diseases. Financing such long-term R&D projects is a key challenge. This chart shows that the debt market is closed to such companies, and their development depends entirely on their ability to attract equity capital from investors.
P/E of the company, segment and market as a whole
P/E - CMMB
For Chemomab Therapeutics, a biopharmaceutical company, the P/E ratio is irrelevant. The company has no products on the market and, therefore, no profit. Any values on this chart are random. Investors evaluate solely the scientific potential of its experimental drugs.
P/E of the market segment - Specialized pharma
Chemomab Therapeutics is a clinical-stage biopharmaceutical company developing novel treatments for fibroinflammatory diseases such as scleroderma and NASH. This chart shows the average valuation for the sector, providing investors with context for assessing Chemomab's scientific potential.
P/E of the market as a whole
Chemomab Therapeutics is a biopharmaceutical company developing drugs for the treatment of fibroinflammatory diseases. Its valuation is entirely dependent on the success of its clinical programs. Overall market sentiment, reflected in this chart, is irrelevant. Chemomab's fate is decided by clinical data reports, not inflation reports.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company CMMB
Chemomab Therapeutics is a clinical-stage biopharmaceutical company developing antibodies for the treatment of fibroinflammatory diseases. This chart reflects investor expectations for the clinical trials of its lead drug. The valuation is based on the potential to offer a new approach to the treatment of scleroderma and other rare diseases.
%20P%2FE%20CMMB&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-CMMB&v=1772544941028 "Chart of the company's future (projected) P/E CMMB")
Future (projected) P/E of the market segment - Specialized pharma
Chemomab Therapeutics is a clinical-stage biopharmaceutical company developing therapies for fibroinflammatory diseases. Its valuation, relative to other biotech companies, reflects investor expectations for its lead drug, demonstrating the market's confidence in its potential to treat liver, skin, and joint diseases.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-pharma&v=1772544941070 "Future (projected) P/E graph of the market segment - Specialized pharma")
Future (projected) P/E of the market as a whole
Chemomab Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat rare fibroinflammatory diseases. Its future depends on the success of clinical trials. This chart reflects the overall risk appetite of investors, which is a key factor in funding long-term, high-risk biotech projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772544941095 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit CMMB
Chemomab Therapeutics is a clinical-stage biopharmaceutical company developing antibodies for the treatment of fibroinflammatory diseases. The financial indicators shown in the graph reflect the costs of conducting clinical trials. The success of its lead drug is key to the company's future.
Profit of companies in the market segment - Specialized pharma
Chemomab Therapeutics is a biotech company developing drugs to treat fibroinflammatory diseases. This chart reflects overall profitability in the specialty pharmaceuticals sector. It helps us understand the commercial potential in treating complex chronic diseases where effective therapies are currently unavailable.
Overall market profit
Chemomab Therapeutics is a biopharmaceutical company developing drugs for the treatment of fibroinflammatory diseases. Its future, like that of many companies in the sector, depends on the results of clinical trials and partnerships with major pharmaceutical companies. This macroeconomic cycle schedule does not affect patient demand for treatment.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company CMMB
Chemomab Therapeutics is a biotechnology company developing drugs for the treatment of fibrotic and inflammatory diseases. Its future profit forecast depends on the success of its lead drug candidate in clinical trials. This chart reflects analyst expectations regarding the scientific potential of its developments and their commercial prospects.
%20profit%20of%20the%20company%20CMMB&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-CMMB&v=1772544941225 "Graph of future (projected) profit of the company CMMB")
Future (predicted) profit of companies in the market segment - Specialized pharma
Chemomab Therapeutics is a biopharmaceutical company developing antibodies for the treatment of fibroinflammatory diseases affecting the liver, skin, and joints. This chart shows forecasts for its segment. It provides investors with context for assessing the potential of targeted therapy for the treatment of complex chronic diseases with high unmet demand.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-pharma&v=1772544941273 "Graph of future (predicted) profits of companies in a market segment - Specialized pharma")
Future (predicted) profit of the market as a whole
For Chemomab Therapeutics, a clinical-stage biopharmaceutical company, this chart is an indicator of capital availability. Positive economic expectations increase investor willingness to finance risky but promising projects. A negative trend could seriously complicate fundraising.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772544941313 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - CMMB
Chemomab Therapeutics develops drugs to treat fibroinflammatory diseases. Without commercial revenue, its valuation, as shown in this chart, is based entirely on expectations. Investors are betting on the success of its clinical trials.
P/S market segment - Specialized pharma
Chemomab Therapeutics is a biopharmaceutical company developing drugs to treat fibrotic and inflammatory diseases. This chart shows the average valuation in the specialty pharmaceuticals sector. It reflects investor expectations for the potential of Chemomab's unique antibody, which targets a key protein involved in fibrosis and inflammation.
P/S of the market as a whole
Chemomab Therapeutics Ltd. is a clinical-stage biopharmaceutical company developing an antibody for the treatment of rare fibrotic and inflammatory diseases. The company's valuation is based on the potential of its lead drug candidate. This chart helps investors compare this expectation-based valuation with realistic revenue estimates in other sectors.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company CMMB
Chemomab Therapeutics is a biopharmaceutical company developing antibodies for the treatment of fibroinflammatory diseases. Its valuation is based on the future potential of its lead drug candidate. The chart reflects investors' confidence in the success of clinical trials and the drug's commercial potential in major markets.
%20P%2FS%20CMMB&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-CMMB&v=1772544941569 "The graph of the company's future (projected) P/S CMMB")
Future (projected) P/S of the market segment - Specialized pharma
Chemomab Therapeutics is a clinical-stage biopharmaceutical company developing antibodies for the treatment of fibroinflammatory diseases, such as liver and skin conditions. Its lead drug targets a key protein that causes fibrosis. This chart shows how investors view the potential of its targeted therapy compared to other biotech companies.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-pharma&v=1772544941632 "Future (projected) P/S market segment graph - Specialized pharma")
Future (projected) P/S of the market as a whole
This chart shows general expectations for the biotech market. For Chemomab Therapeutics, a company developing drugs to treat fibroinflammatory diseases, it's an indicator of the investment climate. Market optimism allows it to attract capital for research into rare diseases with high unmet treatment needs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772544941723 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales CMMB
Chemomab Therapeutics is a clinical-stage biopharmaceutical company developing an antibody for the treatment of rare fibroinflammatory diseases of the liver and skin. This chart represents revenue from partnerships. In the future, it will reflect sales revenue for the drug following its successful approval for the treatment of conditions such as primary sclerosing cholangitis.
Sales of companies in the market segment - Specialized pharma
Chemomab Therapeutics is a clinical-stage biopharmaceutical company developing therapies for the treatment of fibroinflammatory diseases. This chart shows the dynamics of the specialty pharmaceutical sector. Chemomab's unique approach targets a key protein involved in these processes, which could lead to the creation of a new class of drugs.
Overall market sales
Chemomab Therapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of fibroinflammatory diseases. Its development depends on successful clinical trials. The overall economic situation, shown in this chart, affects the availability of capital to fund lengthy and expensive research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company CMMB
Chemomab Therapeutics is a clinical-stage biopharmaceutical company developing antibodies for the treatment of fibroinflammatory diseases, such as liver and skin diseases. The company's future depends on the success of its clinical programs. This chart reflects analysts' assessment of the scientific potential and commercial prospects of the company's lead drug candidate.
%20sales%20of%20the%20company%20CMMB&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-CMMB&v=1772544942032 "Schedule of future (projected) sales of the company CMMB")
Future (projected) sales of companies in the market segment - Specialized pharma
Chemomab Therapeutics is a biopharmaceutical company developing therapies for fibroinflammatory diseases. This chart shows expectations for the specialty pharmaceuticals sector. It helps understand the potential analysts see in treating the complex chronic diseases Chemomab focuses on.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-pharma&v=1772544942130 "Schedule of future (projected) sales of companies in the market segment - Specialized pharma")
Future (projected) sales of the market as a whole
Chemomab Therapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of fibroinflammatory diseases. Its future depends on successful clinical trials. The overall economic situation, reflected in this chart, influences funding levels in the biotech sector and the willingness of large pharmaceutical companies to partner and acquire.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772544942236 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality CMMB
Chemomab Therapeutics is a biopharmaceutical company developing drugs for the treatment of fibroinflammatory diseases. This chart reflects the clinical trial stage. Negative values represent investments in the development of its lead candidate, which, if successful, could become first-in-class and generate significant profits.
Market segment marginality - Specialized pharma
Chemomab Therapeutics is a biopharmaceutical company developing treatments for fibroinflammatory diseases. This chart serves as a benchmark for companies in clinical trials. It shows the average profitability achieved by successful companies in their sector, illustrating the financial potential should their drugs be approved.
Market marginality as a whole
Chemomab Therapeutics is a biopharmaceutical company developing treatments for rare fibroinflammatory diseases. This total market profitability graph does not impact its operations. Its potential lies in its unique approach to treating these complex conditions. Success will be determined by clinical data, not by general economic trends.
Employees in the company, segment and market as a whole
Number of employees in the company CMMB
Chemomab Therapeutics is a biopharmaceutical company developing drugs for the treatment of fibroinflammatory diseases. This graph shows a small scientific and clinical team. Their size is typical for a company whose primary asset is a promising drug candidate undergoing clinical trials.
Share of the company's employees CMMB within the market segment - Specialized pharma
Chemomab Therapeutics develops antibodies to treat fibroinflammatory diseases. In this complex field of biotechnology, a strong team of scientists is a key asset. This chart shows the percentage of leading biologists and immunologists specializing in fibrosis that the company employs, reflecting its concentration of unique scientific expertise for the development of breakthrough drugs.
Number of employees in the market segment - Specialized pharma
Chemomab Therapeutics is a biopharmaceutical company developing antibodies for the treatment of fibroinflammatory diseases. Fibrosis treatment is a promising area of medicine. This graph illustrates how fundamental research in biology is opening up new therapeutic areas and creating a demand for highly specialized research scientists.
Number of employees in the market as a whole
Chemomab Therapeutics is a biopharmaceutical company, and its example illustrates how capital-intensive this industry is. Funding research and hiring scientists requires enormous investments. This total employment graph reflects the economy's ability to channel capital into long-term, risky projects that create innovation and jobs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company CMMB (CMMB)
Chemomab Therapeutics is a biotech company developing treatments for fibroinflammatory diseases. This chart is a classic example of intellectual capital valuation. The company's value is based on market expectations for its lead drug candidate (CM-101). The chart shows the high future value the market attributes to this development, per scientist.
%20of%20the%20company%20CMMB%20(CMMB)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-CMMB-CMMB&v=1772544942833 "Chart of market capitalization per employee (in thousands of dollars) of the company CMMB (CMMB)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized pharma
Chemomab Therapeutics develops drugs to treat fibroinflammatory diseases. In this biotech field, the company's value lies in its scientific platform. The chart shows how much investors are betting on Chemomab's research team. This allows one to compare market expectations for their developments with those of other biotech companies.
%20by%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-pharma&v=1772544942957 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized pharma")
Market capitalization per employee (in thousands of dollars) for the overall market
Chemomab Therapeutics is a biopharmaceutical company developing treatments for fibroinflammatory diseases. This chart shows the overall market productivity valuation, highlighting the value of scientific innovation.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772544943014 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company CMMB (CMMB)
Chemomab Therapeutics is a clinical-stage biotech company with no commercial products. This chart shows the net loss per employee. It reflects not inefficiency, but the company's "bet"—how much it invests in each scientist to conduct research and develop breakthrough therapies.
%20Chart%20CMMB%20(CMMB)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-CMMB-CMMB&v=1772544943114 "Company Profit Per Employee (in thousands of dollars) Chart CMMB (CMMB)")
Profit per employee (in thousands of dollars) in the market segment - Specialized pharma
Chemomab Therapeutics is a clinical-stage biopharmaceutical company developing therapies for fibroinflammatory diseases. Its primary asset is its research and development team. This graph for such companies typically shows negative earnings per employee, reflecting high investments in R&D in anticipation of the drug's future commercial success.
%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-pharma&v=1772544943131 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized pharma")
Profit per employee (in thousands of dollars) for the market as a whole
Chemomab Therapeutics (CMMB) is an Israeli clinical-stage biotech company developing antibodies for the treatment of fibroinflammatory liver disease (NASH) and skin diseases. It's an R&D company. This chart shows the market average dollar return per employee. For CMMB (which is not yet profitable), this is a benchmark: in biotech, IP can significantly exceed this average.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772544943191 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee CMMB (CMMB)
Chemomab Therapeutics is a clinical-stage biopharmaceutical company developing treatments for fibrotic diseases. This graph is a proxy for the future. It reflects the potential for successful drug development and commercialization to lead to significant revenue growth per employee.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-CMMB-CMMB&v=1772544943351 "Sales chart per company employee CMMB (CMMB)")
Sales per employee in the market segment - Specialized pharma
Chemomab Therapeutics is a clinical-stage biotech company focused on the treatment of fibroinflammatory diseases. Revenue is not yet available. This chart shows the average revenue per employee in the segment, which serves as a benchmark for commercial pharmaceutical companies. It provides context for assessing the effectiveness of Chemomab's workforce.
Sales per employee for the market as a whole
Chemomab Therapeutics is a clinical-stage biotechnology company developing therapies for rare inflammatory and fibrotic diseases. The company has no commercial products and, therefore, no revenue. This metric is currently irrelevant. The company's entire value lies in its R&D platform.
Short shares by company, segment and market as a whole
Shares shorted by company CMMB (CMMB)
Chemomab is an Israeli clinical-stage biotech company developing a drug to treat rare fibrotic (inflammatory) liver and skin diseases. This chart shows the number of "bears" betting that their scientific approach will be flawed, the trials will fail, and the company will burn through all its capital.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-CMMB-CMMB&v=1772544943481 "Short Shares Chart for the Company CMMB (CMMB)")
Shares shorted by market segment - Specialized pharma
Chemomab Therapeutics is a biotech company developing therapies for rare fibroinflammatory diseases of the liver and skin. This indicator reflects the overall volume of short positions in the pharmaceutical sector. An increase in short positions here may indicate that investors perceive a high risk of clinical trial failures for this complex therapeutic area.
Shares shorted by the overall market
Chemomab is a biotech company working on rare inflammatory diseases. It has a long R&D cycle. This chart illustrates the overall market pessimism. When investors panic, they're unwilling to fund multi-year trials. They see the risk of failure and sell off biotech stocks that lack stable revenue.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator CMMB (CMMB)
This oscillator for Chemomab is a barometer of hope in the treatment of rare fibrotic diseases (liver, skin). The company is developing a drug targeting a key fibrosis protein. "Overbought" (above 70) is emerging due to positive Phase 2 data. The complexity of these diseases and the high risk of failure in Phase 3 keep investors on edge, leading to "oversold" conditions.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-CMMB-CMMB&v=1772544943595 "RSI 14 indicator chart for the company's stock CMMB (CMMB)")
RSI 14 Market Segment - Specialized pharma
Chemomab (CMMB) is an Israeli biotech company focused on fibrosis. Their signature product is an antibody (CM-101) that attacks a key protein (CCL24) in fibro-inflammatory diseases (liver/PSC, skin). The Specialized Pharma (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of the entire segment. It helps us understand: is CMMB's growth driven by R&D, or is the entire biotech sector overheated?
RSI 14 for the overall market
Chemomab (CMMB) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CMMB (CMMB)
Chemomab Therapeutics is a biotech company developing drugs for the treatment of fibrotic and inflammatory diseases of the liver and skin. This chart shows the average 12-month forecast of analysts. It represents their collective speculative bet on the success of clinical trials of their lead candidate, CM-101.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CMMB-CMMB&v=1772544943757 "A chart showing analyst consensus forecasts for the expected stock price. CMMB (CMMB)")
The difference between the consensus estimate and the actual stock price CMMB (CMMB)
Chemomab is an Israeli biotech company developing an antibody (CM-101) for the treatment of fibroinflammatory diseases of the liver and skin. This chart shows the difference between the market valuation and the consensus forecast. It indicates whether experts believe in their R&D approach and the chances of success in complex clinical trials.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CMMB-CMMB&v=1772544943773 "A chart showing the difference between the consensus forecast and the actual stock price. CMMB (CMMB)")
Analyst consensus forecast for stock prices by market segment - Specialized pharma
Chemomab is an Israeli biotech developing drugs to treat rare inflammatory liver and skin diseases. This is risky R&D. This chart reflects analysts' overall expectations for the entire specialty pharma sector. It shows whether experts believe in the success of junior biotechs or consider the sector overheated.
Analysts' consensus forecast for the overall market share price
Chemomab is an Israeli biotech company developing drugs to treat rare fibroinflammatory diseases of the liver and skin. This chart reflects the overall market "risk appetite." For Chemomab, a high-risk clinical-stage company, overall market optimism (risk appetite) is critical to attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index CMMB
Chemomab is an Israeli biotech company focused on fibrosis (scarring). Their flagship R&D drug (CM-101) is an antibody designed to treat rare but fatal liver and skin diseases caused by fibrosis. This chart is a pure indicator of faith in their R&D. It doesn't reflect revenue, but rather a speculative valuation of their (very risky) pipeline.
AKIMA Market Segment Index - Specialized pharma
Chemomab Therapeutics (CMMB) is an Israeli biopharmaceutical company developing drugs to treat fibroinflammatory diseases such as NASH (a liver disease) and scleroderma. The chart shows the average index for the segment, helping investors assess how CMMB's risks in this complex area compare to the industry average.
The AKIM Index for the overall market
Chemomab Therapeutics is a biotech company developing treatments for fibrotic and inflammatory diseases (primary sclerosing cholangitis). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this clinical-stage research project compares to overall economic trends.
